文献速递心力衰竭与心肌病

信号体调控SRF磷酸化决定心肌细胞宽度与长度生长并作为心衰治疗靶点

Signalosome-Regulated Serum Response Factor Phosphorylation Determining Myocyte Growth in Width Versus Length as a Therapeutic Target for Heart Failure.
PubMed 文献 · Circulation · 2020-09-16

该研究在大鼠心室肌细胞、小鼠AAV基因递送及人心脏组织中,揭示mAKAPβ信号体通过RSK3/PP2A双向调控SRF Ser103磷酸化,构成决定心肌细胞向宽度或长度生长的表观遗传开关。抑制RSK3可预防压力过载所致向心性重构,抑制PP2A可预防心梗所致离心性重构,两者均改善心功能;人扩张型心肌病心脏中SRF Ser103磷酸化显著降低,提示该信号体是心衰治疗新靶点。

要点

  • SRF Ser103磷酸化是决定心肌细胞向宽度或长度生长的表观遗传开关。
  • mAKAPβ信号体中RSK3与PP2A双向调控SRF Ser103磷酸化。
  • 靶向mAKAPβ信号体的AAV基因治疗可分别预防向心性或离心性重构。

核心结论

  • mAKAPβ信号体调控的SRF磷酸化是控制病理性应激下心肌细胞形态变化的分子开关,基于AAV的互补基因治疗是心衰转化治疗的新策略。

研究设计与样本

  • 研究使用原代成年大鼠心室肌细胞、小鼠AAV介导的基因递送以及人体组织样本,定义控制病理性心肌细胞肥大的调控通路。
  • 采用染色质免疫沉淀测序和精确定核run-on测序定义转录机制。

主要发现

  • SRF Ser103磷酸化受RSK3与PP2A在mAKAPβ支架蛋白组织的信号体上双向调控,磷酸化增加激活AP-1依赖的增强子,引导心肌细胞向宽度生长。
  • 抑制RSK3信号可预防压力过载诱导的向心性心脏重构,抑制PP2A信号可预防心肌梗死诱导的离心性心脏重构,两者均改善心脏功能。
  • 人扩张型心肌病心脏中SRF Ser103磷酸化显著降低。

临床怎么用

  • 调控mAKAPβ-SRF信号体可能成为人心衰的新治疗途径。
  • AAV递送mAKAPβ来源的RSK3和PP2A锚定干扰肽构成合理设计的转化治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concentric and eccentric cardiac hypertrophy are associated with pressure and volume overload, respectively, in cardiovascular disease both conferring an increased risk of heart failure. These contrasting forms of hypertrophy are characterized by asymmetrical growth of the cardiac myocyte in mainly width or length, respectively. The molecular mechanisms determining myocyte preferential growth in width versus length remain poorly understood. Identification of the mechanisms governing asymmetrical myocyte growth could provide new therapeutic targets for the prevention or treatment of heart failure. METHODS: Primary adult rat ventricular myocytes, adeno-associated virus (AAV)-mediated gene delivery in mice, and human tissue samples were used to define a regulatory pathway controlling pathological myocyte hypertrophy. Chromatin immunoprecipitation assays with sequencing and precision nuclear run-on sequencing were used to define a transcriptional mechanism. RESULTS: We report that asymmetrical cardiac myocyte hypertrophy is modulated by SRF (serum response factor) phosphorylation, constituting an epigenomic switch balancing the growth in width versus length of adult ventricular myocytes in vitro and in vivo. SRF Ser103 phosphorylation is bidirectionally regulated by RSK3 (p90 ribosomal S6 kinase type 3) and PP2A (protein phosphatase 2A) at signalosomes organized by the scaffold protein mAKAPβ (muscle A-kinase anchoring protein β), such that increased SRF phosphorylation activates AP-1 (activator protein-1)-dependent enhancers that direct myocyte growth in width. AAV are used to express in vivo mAKAPβ-derived RSK3 and PP2A anchoring disruptor peptides that block the association of the enzymes with the mAKAPβ scaffold. Inhibition of RSK3 signaling prevents concentric cardiac remodeling induced by pressure overload, while inhibition of PP2A signaling prevents eccentric cardiac remodeling induced by myocardial infarction, in each case improving cardiac function. SRF Ser103 phosphorylation is significantly decreased in dilated human hearts, supporting the notion that modulation of the mAKAPβ-SRF signalosome could be a new therapeutic approach for human heart failure. CONCLUSIONS: We have identified a new molecular switch, namely mAKAPβ signalosome-regulated SRF phosphorylation, that controls a transcriptional program responsible for modulating changes in cardiac myocyte morphology that occur secondary to pathological stressors. Complementary AAV-based gene therapies constitute rationally-designed strategies for a new translational modality for heart failure.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Li J, Tan Y, Passariello CL, et al. Signalosome-Regulated Serum Response Factor Phosphorylation Determining Myocyte Growth in Width Versus Length as a Therapeutic Target for Heart Failure. Circulation. 2020. PMID: 32933333. doi:10.1161/CIRCULATIONAHA.119.044805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。